

Clinical validation of the detection of KRAS and BRAF m DNA

Nature Medicine

20, 430-435

DOI: [10.1038/nm.3511](https://doi.org/10.1038/nm.3511)

Citation Report

#	ARTICLE	IF	CITATIONS
4	Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1979-1989.	0.9	41
5	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 380-394.	1.0	1
6	KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 104.	3.5	36
7	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , 2014, 128, 879-891.	3.9	54
8	Targeted therapy in melanoma: the era of personalized medicine. <i>Diagnostic Histopathology</i> , 2014, 20, 425-430.	0.2	1
9	Changing the paradigm: circulating tumor DNA as a "liquid biopsy"™ for clinical biomarker assessments. <i>Clinical Investigation</i> , 2014, 4, 1083-1093.	0.0	1
10	Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. <i>Annals of Oncology</i> , 2014, 25, 2304-2313.	0.6	138
11	CCR : d'Épistage sur l'ADN tumoral circulant. <i>Option/Bio</i> , 2014, 25, 10.	0.0	0
12	Non-invasive pre-implantation genetic diagnosis of X-linked disorders. <i>Medical Hypotheses</i> , 2014, 83, 506-508.	0.8	36
13	RAS testing of colorectal carcinoma" a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. <i>Journal of Clinical Pathology</i> , 2014, 67, 751-757.	1.0	66
15	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <i>Molecular Oncology</i> , 2014, 8, 927-941.	2.1	192
16	The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. <i>Blood</i> , 2014, 124, 2610-2611.	0.6	26
17	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. <i>The Journal of Oncopathology</i> , 2014, 2, 37-45.	0.1	0
18	Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2015, 102, 1175-1183.	0.1	171
19	Early Cancer Diagnosis with ctDNA as a Liquid Biopsy Target. <i>Gene and Gene Editing</i> , 2015, 1, 67-69.	0.0	0
20	Liquid biopsy. <i>Current Opinion in Oncology</i> , 2015, 27, 560-567.	1.1	35
23	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
24	Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. <i>Frontiers in Oncology</i> , 2015, 5, 209.	1.3	48

#	ARTICLE	IF	CITATIONS
25	SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. PLoS ONE, 2015, 10, e0142273.	1.1	30
26	Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations. PLoS ONE, 2015, 10, e0145698.	1.1	8
28	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget, 2015, 6, 2549-2561.	0.8	96
29	Pre-analytical Requirements for Analyzing Nucleic Acids from Blood. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 45-69.	0.6	4
30	Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 2015, 47, 884-890.	0.4	59
31	An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum. Nature Chemistry, 2015, 7, 569-575.	6.6	234
32	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. Expert Review of Molecular Diagnostics, 2015, 15, 1631-1644.	1.5	53
33	Actualizaci3n de la recomendaci3n para la determinaci3n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espaola de AnatomA Patol3gica y de la Sociedad Espaola de OncologA M3dica. Revista Espanola De Patologia, 2015, 48, 14-24.	0.6	1
34	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematology,the, 2015, 2, e55-e65.	2.2	115
35	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
36	Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology, 2015, 9, 783-790.	2.1	248
37	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2015, 17, 264-273.	1.2	11
39	Some economics on personalized and predictive medicine. European Journal of Health Economics, 2015, 16, 985-994.	1.4	18
40	Colorectal cancer: using blood samples and tumor tissue to detectK-rasmutations. Expert Review of Anticancer Therapy, 2015, 15, 715-725.	1.1	6
41	Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Analytical and Bioanalytical Chemistry, 2015, 407, 6873-6878.	1.9	91
42	Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD. EBioMedicine, 2015, 2, 929-936.	2.7	83
43	Genetic Intratumor Heterogeneity. , 2015, , 571-593.		2
44	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. Lancet Oncology, The, 2015, 16, 878-879.	5.1	3

#	ARTICLE	IF	CITATIONS
45	Cell-free DNA as a novel marker in cancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 703-712.	0.6	13
46	Association Between Specific Mutations in <i>KRAS</i> Codon 12 and Colorectal Liver Metastasis. <i>JAMA Surgery</i> , 2015, 150, 722.	2.2	108
48	Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. <i>Clinical Chemistry</i> , 2015, 61, 838-849.	1.5	94
49	Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 366-373.	1.2	34
50	Accessing Genetic Information with Liquid Biopsies. <i>Trends in Genetics</i> , 2015, 31, 564-575.	2.9	121
51	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. <i>Cancer Cell</i> , 2015, 28, 666-676.	7.7	700
52	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. <i>Clinical Cancer Research</i> , 2015, 21, 4786-4800.	3.2	310
54	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	1.3	48
55	Clinical utility of circulating tumor DNA in human cancers. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 222-226.	0.3	2
56	Liquid biopsy for cancer patients: Principles and practice. <i>Pathogenesis</i> , 2015, 2, 1-4.	0.8	31
57	Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , .	0.6	8
58	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. <i>Clinical Chemistry</i> , 2015, 61, 297-304.	1.5	221
59	Circulating Tumor DNA as a Liquid Biopsy for Cancer. <i>Clinical Chemistry</i> , 2015, 61, 112-123.	1.5	654
60	Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. <i>Clinica Chimica Acta</i> , 2015, 439, 97-101.	0.5	33
61	Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report. <i>Acta Dermato-Venereologica</i> , 2016, 96, 128-129.	0.6	8
62	Clinical applications of liquid biopsies in gastrointestinal oncology. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 675-686.	0.6	10
63	Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer. <i>Genes</i> , 2016, 7, 125.	1.0	47
64	KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 484.	1.8	40

#	ARTICLE	IF	CITATIONS
65	Fragment Length of Circulating Tumor DNA. PLoS Genetics, 2016, 12, e1006162.	1.5	502
66	Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. PLoS Medicine, 2016, 13, e1002199.	3.9	76
67	Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes. Disease Markers, 2016, 2016, 1-5.	0.6	60
68	The State of the Art in Colorectal Cancer Molecular Biomarker Testing. Advances in Anatomic Pathology, 2016, 23, 92-103.	2.4	9
69	Origins, structures, and functions of circulating DNA in oncology. Cancer and Metastasis Reviews, 2016, 35, 347-376.	2.7	586
70	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
71	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. Chronic Diseases and Translational Medicine, 2016, 2, 223-230.	0.9	30
72	Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. Clinical Chemistry, 2016, 62, 1492-1503.	1.5	68
73	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 2016, 27, 1443-1448.	0.6	79
74	Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing. Clinical Breast Cancer, 2016, 16, 418-423.	1.1	28
75	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
76	Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. International Journal of Clinical Oncology, 2016, 21, 981-988.	1.0	35
77	<i>KRAS</i> mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer, 2016, 5, 73-80.	0.8	0
78	Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 181-194.	0.4	1
79	Circulating cell-free DNA in hematological malignancies. Haematologica, 2016, 101, 997-999.	1.7	16
80	PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer, 2016, 16, 627.	1.1	40
81	Peripheral blood cell-free <i>DNA</i> is an alternative tumor <i>DNA</i> source reflecting disease status in myelodysplastic syndromes. Cancer Science, 2016, 107, 1329-1337.	1.7	20
82	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2016, 22, 5480-5486.	3.2	84

#	ARTICLE	IF	CITATIONS
83	Biosensors for liquid biopsy: circulating nucleic acids to diagnose and treat cancer. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 7255-7264.	1.9	60
84	DNA Clutch Probes for Circulating Tumor DNA Analysis. <i>Journal of the American Chemical Society</i> , 2016, 138, 11009-11016.	6.6	169
85	Utility of <i>KRAS</i> mutation detection using circulating cell-free DNA from patients with colorectal cancer. <i>Cancer Science</i> , 2016, 107, 936-943.	1.7	77
86	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 267-282.	1.0	7
87	Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules. <i>Chemical Reviews</i> , 2016, 116, 9001-9090.	23.0	702
88	Establishment and application of a real-time loop-mediated isothermal amplification system for the detection of CYP2C19 polymorphisms. <i>Scientific Reports</i> , 2016, 6, 26533.	1.6	28
89	A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 124.	3.5	66
90	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863
91	Hematopoietic stem cells meet induced pluripotent stem cells technology. <i>Haematologica</i> , 2016, 101, 999-1001.	1.7	6
92	mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 147-155.	0.8	23
93	Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. <i>Molecular Oncology</i> , 2016, 10, 1575-1584.	2.1	61
94	Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. <i>Nucleic Acids Research</i> , 2016, 44, gkw650.	6.5	55
95	Implementing personalized medicine with asymmetric information on prevalence rates. <i>Health Economics Review</i> , 2016, 6, 35.	0.8	2
96	Comparison of <i>KRAS</i> mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. <i>Medical Oncology</i> , 2016, 33, 71.	1.2	12
97	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
98	Technological advances in precision medicine and drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 331-343.	0.4	9
99	Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict <i>KRAS</i> mutations before surgery. <i>Molecular Oncology</i> , 2016, 10, 1221-1231.	2.1	78
100	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. <i>Gut</i> , 2016, 65, 625-634.	6.1	381

#	ARTICLE	IF	CITATIONS
101	Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. <i>Molecular Oncology</i> , 2016, 10, 494-502.	2.1	63
102	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. <i>Molecular Oncology</i> , 2016, 10, 635-643.	2.1	131
103	Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Molecular Oncology</i> , 2016, 10, 475-480.	2.1	52
104	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 95-103.	1.0	30
105	Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). <i>Analyst, The</i> , 2016, 141, 393-402.	1.7	23
106	Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 239-252.	1.5	36
107	Circulating Cell Free DNA in the Diagnosis of Trophoblastic Tumors. <i>EBioMedicine</i> , 2016, 4, 146-152.	2.7	23
108	RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 2635-2643.	0.7	119
109	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <i>Clinical Cancer Research</i> , 2016, 22, 3067-3077.	3.2	144
111	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. <i>European Journal of Cancer</i> , 2016, 54, 75-83.	1.3	145
112	Circulating DNA in solid organ cancers—analysis and clinical application. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 223-227.	0.2	15
113	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	3.2	53
114	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017, 183, 137-154.	2.2	14
115	Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 737-744.	0.9	3
116	Circulating nucleic acids: An analysis of their occurrence in malignancies. <i>Biomedical Reports</i> , 2017, 6, 8-14.	0.9	29
117	Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. , 2017, 174, 22-26.		28
118	Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 755-768.	1.1	198
119	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	12.8	1,786

#	ARTICLE	IF	CITATIONS
121	Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. <i>BMC Cancer</i> , 2017, 17, 29.	1.1	21
122	HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, 247-251.	1.0	32
123	Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 531-548.	12.5	1,375
124	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	1.8	23
125	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	3.2	70
126	<i>PIK3CA</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4602-4616.	3.2	72
127	Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1817-1833.	1.4	13
128	Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 525-536.	1.2	64
129	Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. <i>Translational Research</i> , 2017, 185, 58-84.e15.	2.2	124
130	Circulating cell-free <i>BRAF</i> ^{V600E} as a biomarker in children with Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2017, 178, 457-467.	1.2	57
131	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	7.7	341
132	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 514-524.	1.2	22
133	KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population. <i>Oncology Letters</i> , 2017, 13, 3608-3616.	0.8	43
135	Potential and Challenges of Liquid Biopsies. , 2017, , 233-261.		0
136	Use of Dimethyl Pimelimidate with Microfluidic System for Nucleic Acids Extraction without Electricity. <i>Analytical Chemistry</i> , 2017, 89, 7502-7510.	3.2	18
137	Ru(bpy) ₃ ²⁺ Incorporated Luminescent Polymer Dots: Double-Enhanced Electrochemiluminescence for Detection of Single-Nucleotide Polymorphism. <i>Analytical Chemistry</i> , 2017, 89, 7659-7666.	3.2	77
138	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
139	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1294-1301.	0.6	150

#	ARTICLE	IF	CITATIONS
140	Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. <i>Cancer Medicine</i> , 2017, 6, 962-974.	1.3	27
141	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 145-159.	0.9	1
142	Application of single-cell technology in cancer research. <i>Biotechnology Advances</i> , 2017, 35, 443-449.	6.0	48
143	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	1.6	141
144	Blood-Based Diagnostics in Solid Tumors: An Overview. <i>Cancer Drug Discovery and Development</i> , 2017, , 1-13.	0.2	1
145	A carbon nanotube reporter of microRNA hybridization events in vivo. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	160
146	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 293-301.	1.8	79
147	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Colon and Rectum</i> , 2017, 11, 117-118.	0.0	5
148	Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. <i>Acta OncolÁgica</i> , 2017, 56, 7-16.	0.8	33
149	Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients. <i>Clinica Chimica Acta</i> , 2017, 465, 1-4.	0.5	29
150	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. <i>Annals of Oncology</i> , 2017, 28, 468-477.	0.6	62
151	MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , 2017, 28, 642-650.	0.6	41
152	Tumor Evolution as a Therapeutic Target. <i>Cancer Discovery</i> , 2017, 7, 805-817.	7.7	158
153	Liquid Biopsy in Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , .	0.0	6
154	Liquid Biopsy in Colorectal Cancer. <i>Current Clinical Pathology</i> , 2017, , 117-124.	0.0	0
155	Precision medicine in gastric cancer: where are we now?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 193-204.	0.4	0
156	Anchored protease-activatable polymersomes for molecular diagnostics of metastatic cancer cells. <i>Journal of Materials Chemistry B</i> , 2017, 5, 9571-9578.	2.9	14
157	Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. <i>Tumor Biology</i> , 2017, 39, 101042831773151.	0.8	20

#	ARTICLE	IF	CITATIONS
158	Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. <i>Scientific Reports</i> , 2017, 7, 14605.	1.6	22
159	Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 409-416.	0.8	30
160	Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. <i>Clinical Chemistry</i> , 2017, 63, 1605-1613.	1.5	23
161	Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. <i>Annals of Oncology</i> , 2017, 28, 2149-2159.	0.6	87
162	Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 15-24.	4.0	70
163	Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 24-34.	1.2	65
164	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 25-40.	4.0	87
165	Emerging technologies for salivaomics in cancer detection. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 640-647.	1.6	55
166	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 580-590.	0.3	2
167	Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e92-e95.	1.4	1
168	Cell-free DNA as a post-treatment surveillance strategy: current status. <i>Seminars in Oncology</i> , 2017, 44, 330-346.	0.8	20
169	Circulating Tumor DNA is Effective for Detection of KRAS Mutation in Colorectal Cancer: A Meta-Analysis. <i>International Journal of Biological Markers</i> , 2017, 32, 421-427.	0.7	12
170	Direct characterization of circulating DNA in blood plasma using $\hat{1}/4$ LAS technology. , 2017, , .		0
171	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	0.8	45
172	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. <i>Blood Advances</i> , 2017, 1, 352-356.	2.5	29
173	Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1212-1218.	0.6	29
174	Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis. <i>Molecules</i> , 2017, 22, 1951.	1.7	83
175	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. <i>BMC Cancer</i> , 2017, 17, 697.	1.1	94

#	ARTICLE	IF	CITATIONS
176	Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 945-953.	1.0	32
177	Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1363-1374.	0.9	59
178	Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated <i>BCAT1</i> and <i>IKZF1</i> DNA. <i>Journal of applied laboratory medicine</i> , The, 2017, 2, 165-175.	0.6	9
179	Rapid and accurate detection of <i>KRAS</i> mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics. <i>Oncotarget</i> , 2017, 8, 83860-83871.	0.8	15
180	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 548-560.	1.8	21
181	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 55632-55645.	0.8	116
182	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.	0.6	26
183	Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of <i>KRAS</i> mutations using Intplex allele-specific PCR. <i>Oncotarget</i> , 2017, 8, 86253-86263.	0.8	64
184	Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. <i>Clinica Chimica Acta</i> , 2018, 481, 34-41.	0.5	16
185	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 2688-2699.	3.2	45
186	Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. <i>Journal of Dental Research</i> , 2018, 97, 701-708.	2.5	92
187	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 467-475.	1.5	7
188	Who Needs This Junk, or Genomic Dark Matter. <i>Biochemistry (Moscow)</i> , 2018, 83, 450-466.	0.7	28
189	Combinatorial Probes for High-Throughput Electrochemical Analysis of Circulating Nucleic Acids in Clinical Samples. <i>Angewandte Chemie</i> , 2018, 130, 3773-3778.	1.6	14
190	Clinical indications for, and the future of, circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 143-150.	6.6	57
191	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 396-402.	0.7	14
192	Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring. <i>Lab on A Chip</i> , 2018, 18, 1320-1329.	3.1	48
193	Should Liquid Biopsies Be Considered in Treatment Decisions?. , 2018, , 577-580.		0

#	ARTICLE	IF	CITATIONS
194	Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges. <i>ACS Sensors</i> , 2018, 3, 540-560.	4.0	31
195	Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 975-982.	0.5	36
196	Inhibition of <i>DDR</i> signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	82
197	Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?. <i>Pharmacoeconomics</i> , 2018, 36, 733-743.	1.7	18
198	Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2018, 149, 3-23.	1.0	28
199	A novel cell line generated using the <i>CRISPR</i> / <i>Cas9</i> technology as universal quality control material for <i>KRAS</i> G12V mutation testing. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22391.	0.9	9
200	Combinatorial Probes for High-Throughput Electrochemical Analysis of Circulating Nucleic Acids in Clinical Samples. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 3711-3716.	7.2	59
201	<i>RAS</i> mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018, 29, 1211-1219.	0.6	136
202	Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e1.	1.6	57
203	<i>RAS</i> mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. <i>Digestive and Liver Disease</i> , 2018, 50, 507-512.	0.4	15
204	Extracellular vesicles or free circulating DNA: where to search for <i>BRAF</i> and <i>cKIT</i> mutations?. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 875-882.	1.7	23
205	Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. <i>Annals of Oncology</i> , 2018, 29, 311-323.	0.6	74
206	DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA. <i>Nucleic Acids Research</i> , 2018, 46, e24-e24.	6.5	28
207	Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 16.	3.5	44
208	Preconcentration of DNA using magnetic ionic liquids that are compatible with real-time PCR for rapid nucleic acid quantification. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 4135-4144.	1.9	49
209	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1310-1318.	1.9	40
210	Circulating cell-free DNA for non-invasive cancer management. <i>Cancer Genetics</i> , 2018, 228-229, 169-179.	0.2	71
211	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47.	0.9	31

#	ARTICLE	IF	CITATIONS
212	A simple and robust real-time qPCR method for the detection of PIK3CA mutations. <i>Scientific Reports</i> , 2018, 8, 4290.	1.6	28
213	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. <i>Lab on A Chip</i> , 2018, 18, 1174-1196.	3.1	234
214	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. <i>Pathobiology</i> , 2018, 85, 146-154.	1.9	33
215	Extracellular vesicles compartment in liquid biopsies: Clinical application. <i>Molecular Aspects of Medicine</i> , 2018, 60, 27-37.	2.7	59
216	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
217	Liquid biopsies in gastrointestinal malignancies: when is the big day?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 19-38.	1.1	26
218	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 80-83.	1.0	40
219	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	2.9	324
220	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
221	Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma. <i>Current Medicinal Chemistry</i> , 2018, 25, 558-574.	1.2	11
222	Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	1
223	Control of Probe Density at DNA Biosensor Surfaces Using Poly(L-lysine) with Appended Reactive Groups. <i>Bioconjugate Chemistry</i> , 2018, 29, 4110-4118.	1.8	38
224	New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. <i>Npj Genomic Medicine</i> , 2018, 3, 31.	1.7	71
225	Clinical Interest of Circulating Tumor DNA in Oncology. <i>Archives of Medical Research</i> , 2018, 49, 297-305.	1.5	8
226	TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. <i>Npj Genomic Medicine</i> , 2018, 3, 34.	1.7	26
227	Microfluidic-based solid phase extraction of cell free DNA. <i>Lab on A Chip</i> , 2018, 18, 3459-3470.	3.1	65
228	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3733.	1.8	147
229	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. <i>Cancer Management and Research</i> , 2018, Volume 10, 5895-5908.	0.9	18

#	ARTICLE	IF	CITATIONS
231	Genotyping of Multiple Clinical Samples with a Combined Direct PCR and Magnetic Lateral Flow Assay. IScience, 2018, 7, 170-179.	1.9	9
232	Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Computational and Structural Biotechnology Journal, 2018, 16, 370-378.	1.9	247
233	Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. International Journal of Molecular Sciences, 2018, 19, 3356.	1.8	79
234	TNER: a novel background error suppression method for mutation detection in circulating tumor DNA. BMC Bioinformatics, 2018, 19, 387.	1.2	12
235	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget, 2018, 9, 10259-10271.	0.8	29
236	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5115-E5124.	3.3	114
237	Probing DNA Hybridization Equilibrium by Cationic Conjugated Polymer for Highly Selective Detection and Imaging of Single-Nucleotide Mutation. Analytical Chemistry, 2018, 90, 6804-6810.	3.2	15
238	Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. Clinical Chemistry, 2018, 64, 1338-1346.	1.5	9
239	Circulating tumor DNA, liquid biopsy, and next generation sequencing: A comprehensive technical and clinical applications review. Meta Gene, 2018, 17, 192-201.	0.3	13
240	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 4650-4661.	3.2	63
241	Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clinical Epigenetics, 2018, 10, 63.	1.8	46
242	Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. Advanced Science, 2018, 5, 1800614.	5.6	52
243	Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer. Frontiers in Oncology, 2018, 8, 306.	1.3	9
244	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. Frontiers in Oncology, 2018, 8, 263.	1.3	7
245	Detection of FGFR2-FAM76A Fusion Gene in Circulating Tumor RNA Based on Catalytic Signal Amplification of Graphene Oxide-loaded Magnetic Nanoparticles. Electroanalysis, 2018, 30, 2293-2301.	1.5	24
246	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 1-21.	0.7	60
247	Salivary Exosome and Cell-Free DNA for Cancer Detection. Micromachines, 2018, 9, 340.	1.4	38
248	Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1741-1750.	1.2	38

#	ARTICLE	IF	CITATIONS
249	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
250	Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 55.	3.5	37
251	Liquid biopsy - emergence of a new era in personalized cancer care. <i>Applied Cancer Research</i> , 2018, 38, .	1.0	3
252	Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2018, 18, 421-431.	1.9	31
253	MutScan: fast detection and visualization of target mutations by scanning FASTQ data. <i>BMC Bioinformatics</i> , 2018, 19, 16.	1.2	15
254	Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2473-2480.	1.9	61
255	From validity to clinical utility: the influence of circulating tumor <sc>DNA</sc> on melanoma patient management in a real-world setting. <i>Molecular Oncology</i> , 2018, 12, 1661-1672.	2.1	32
256	Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells. <i>Cancers</i> , 2018, 10, 270.	1.7	15
257	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	1.7	63
259	Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction. <i>Frontiers in Oncology</i> , 2018, 8, 297.	1.3	19
260	Smartphone-based clinical diagnostics: towards democratization of evidence-based health care. <i>Journal of Internal Medicine</i> , 2019, 285, 19-39.	2.7	147
261	Characterizing the Cancer Genome in Blood. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a026880.	2.9	7
262	Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. <i>Scientific Reports</i> , 2019, 9, 11346.	1.6	9
263	Role of Horizontal Gene Transfer in Cancer Progression. , 2019, , 399-425.		0
264	Surface Plasmon Resonance for Biomarker Detection: Advances in Non-invasive Cancer Diagnosis. <i>Frontiers in Chemistry</i> , 2019, 7, 570.	1.8	125
265	<p>Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5745-5756.	0.9	20
266	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. <i>Cell Death and Disease</i> , 2019, 10, 534.	2.7	78
267	<i><sc>RAS</sc></i> and <i><sc>BRAF</sc></i> mutations in cell-free <sc>DNA</sc> are predictive for outcome of cetuximab monotherapy in patients with tissue-tested <i><sc>RAS</sc></i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	2.1	32

#	ARTICLE	IF	CITATIONS
268	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 358-367.	1.2	13
269	Progress in quantitative technique of circulating cell free DNA and its role in cancer diagnosis and prognosis. <i>Cancer Genetics</i> , 2019, 239, 75-84.	0.2	5
270	Thermodynamics and kinetics guided probe design for uniformly sensitive and specific DNA hybridization without optimization. <i>Nature Communications</i> , 2019, 10, 4675.	5.8	28
271	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019, 36, 350-368.	7.7	204
272	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	1.7	36
273	Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102827.	2.0	22
274	Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. <i>Cancer Biomarkers</i> , 2019, 27, 29-37.	0.8	27
275	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	1.1	5
276	Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients. <i>BMC Cancer</i> , 2019, 19, 818.	1.1	16
277	Towards Circulating-Tumor DNA-Based Precision Medicine. <i>Journal of Clinical Medicine</i> , 2019, 8, 1365.	1.0	8
278	Liquid biopsy in combination with solid-state electrochemical sensors and nucleic acid amplification. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6655-6669.	2.9	15
280	Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. <i>Analytical Chemistry</i> , 2019, 91, 13105-13111.	3.2	29
281	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	1.4	27
282	Self-circulating electrochemiluminescence chip for sensitive detection of circulating tumour nucleic acids in blood. <i>Sensors and Actuators B: Chemical</i> , 2019, 301, 127088.	4.0	5
283	Discrimination of the V600E Mutation in BRAF by Rolling Circle Amplification and Förster Resonance Energy Transfer. <i>ACS Sensors</i> , 2019, 4, 2786-2793.	4.0	19
284	Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. <i>Pediatric Research</i> , 2019, 85, 856-864.	1.1	20
285	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 1824-1832.	0.7	31
286	Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. <i>Journal of Pathology</i> , 2019, 247, 641-649.	2.1	53

#	ARTICLE	IF	CITATIONS
287	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. <i>Scientific Reports</i> , 2019, 9, 8976.	1.6	34
288	Branch migration based selective PCR for DNA mutation enrichment and detection. <i>Chemical Communications</i> , 2019, 55, 8466-8469.	2.2	11
289	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz042.	1.4	22
290	Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response. <i>Frontiers in Genetics</i> , 2019, 10, 470.	1.1	29
291	Droplet digital PCR as a novel system for the detection of microRNA-34b/c methylation in circulating DNA in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2019, 54, 2139-2148.	1.4	14
292	Nonfunctionalized PNAs as Beacons for Nucleic Acid Detection in a Nanopore System. <i>ACS Sensors</i> , 2019, 4, 1502-1507.	4.0	13
293	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. <i>Cells</i> , 2019, 8, 516.	1.8	78
294	Efficacy comparison of targeted next-generation sequencing in the identification of somatic mutations in circulating tumor DNA from different stages of lung cancer. <i>Neoplasia</i> , 2019, 66, 652-660.	0.7	7
295	Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 100-129.	2.4	28
296	Cell-free DNA diagnostics: current and emerging applications in oncology. <i>Pharmacogenomics</i> , 2019, 20, 357-380.	0.6	12
297	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
298	<p>The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2539-2552.	1.0	16
299	Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 477-498.	1.5	26
300	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. <i>Annals of Oncology</i> , 2019, 30, 597-603.	0.6	114
301	Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. <i>Journal of Clinical Medicine</i> , 2019, 8, 373.	1.0	107
302	Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker. <i>Clinica Chimica Acta</i> , 2019, 494, 123-131.	0.5	3
303	The emerging role of cell-free DNA as a molecular marker for cancer management. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100087.	7.0	375
304	Quantifying circulating cell-free DNA in humans. <i>Scientific Reports</i> , 2019, 9, 5220.	1.6	145

#	ARTICLE	IF	CITATIONS
305	The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. <i>Molecular Cancer</i> , 2019, 18, 36.	7.9	48
306	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. <i>Drugs</i> , 2019, 79, 633-645.	4.9	32
307	Amplification-free SERS analysis of DNA mutation in cancer cells with single-base sensitivity. <i>Nanoscale</i> , 2019, 11, 7781-7789.	2.8	37
308	Liquid biopsy challenge and hope in colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 341-348.	1.5	8
309	The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 1218-1231.	1.3	15
310	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
311	The next generation personalized models to screen hidden layers of breast cancer tumorigenicity. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 277-286.	1.1	2
312	Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA. <i>Nucleic Acids Research</i> , 2019, 47, e38-e38.	6.5	17
313	A microfluidic alternating-pull-push active digitization method for sample-loss-free digital PCR. <i>Lab on A Chip</i> , 2019, 19, 4104-4116.	3.1	28
315	Combinatory Analysis of Cell-free and Circulating Tumor Cell DNAs Provides More Variants for Cancer Treatment. <i>Anticancer Research</i> , 2019, 39, 6595-6602.	0.5	7
316	Advanced liquid biopsy technologies for circulating biomarker detection. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6670-6704.	2.9	118
317	Cell-Free DNA: An Overview of Sample Types and Isolation Procedures. <i>Methods in Molecular Biology</i> , 2019, 1909, 13-27.	0.4	29
318	Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. <i>Methods in Molecular Biology</i> , 2019, 1909, 47-73.	0.4	19
319	Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients. <i>Translational Oncology</i> , 2019, 12, 426-431.	1.7	35
320	Evaluation of three advanced methodologies, COLD-PCR, microarray and ddPCR, for identifying the mutational status by liquid biopsies in metastatic colorectal cancer patients. <i>Clinica Chimica Acta</i> , 2019, 489, 136-143.	0.5	18
321	Cell-Free Circulating Tumor DNA Mutation Profiling for Cervical Carcinoma as Diagnostic Biomarker: A 50-Gene Module to Future Directive. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	2
322	The cornerstone of integrating circulating tumor DNA into cancer management. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 1-11.	3.3	9
323	Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors. , 2019, , 271-285.		1

#	ARTICLE	IF	CITATIONS
324	Technical considerations for circulating tumor DNA detection in oncology. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 121-135.	1.5	26
325	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	3.4	88
326	Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review. <i>Journal of Surgical Research</i> , 2019, 236, 184-197.	0.8	57
327	Cell-free DNA in cancer: current insights. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 13-28.	2.1	34
328	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. <i>Clinical Cancer Research</i> , 2019, 25, 1216-1225.	3.2	35
329	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	2.3	55
330	Overview of Molecular Testing of Cytology Specimens. <i>Acta Cytologica</i> , 2020, 64, 136-146.	0.7	24
331	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. <i>Acta Clinica Belgica</i> , 2020, 75, 9-18.	0.5	9
332	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
333	High-Performance Nucleic Acid Sensors for Liquid Biopsy Applications. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 2554-2564.	7.2	61
334	High-Performance Nucleic Acid Sensors for Liquid Biopsy Applications. <i>Angewandte Chemie</i> , 2020, 132, 2574-2584.	1.6	54
335	Technical progress in circulating tumor DNA analysis using next generation sequencing. <i>Molecular and Cellular Probes</i> , 2020, 49, 101480.	0.9	19
336	Hypoxia differently modulates the release of mitochondrial and nuclear DNA. <i>British Journal of Cancer</i> , 2020, 122, 715-725.	2.9	14
337	ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. <i>Bioinformatics</i> , 2020, 36, 2665-2674.	1.8	7
338	Liquid Biopsy for Cancer: Review and Implications for the Radiologist. <i>Radiology</i> , 2020, 294, 5-17.	3.6	52
339	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. <i>Cancer Letters</i> , 2020, 472, 108-118.	3.2	8
340	Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer. <i>Analytical Biochemistry</i> , 2020, 590, 113517.	1.1	10
341	BRAF V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors. <i>Cancers</i> , 2020, 12, 66.	1.7	35

#	ARTICLE	IF	CITATIONS
342	Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 1006.	1.1	17
344	Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 15745.	1.6	41
345	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. <i>EBioMedicine</i> , 2020, 62, 103100.	2.7	44
346	Bis(sulfosuccinimidyl)suberate-Based Helix-Shaped Microchannels as Enhancers of Biomolecule Isolation from Liquid Biopsies. <i>Analytical Chemistry</i> , 2020, 92, 11994-12001.	3.2	7
347	Enhancement of Probe Density in DNA Sensing by Tuning the Exponential Growth Regime of Polyelectrolyte Multilayers. <i>Chemistry of Materials</i> , 2020, 32, 9155-9166.	3.2	2
348	PIK3CA mutation enrichment and quantitation from blood and tissue. <i>Scientific Reports</i> , 2020, 10, 17082.	1.6	15
349	Development of circulating tumour DNA analysis for gastrointestinal cancers. <i>ESMO Open</i> , 2020, 5, e000600.	2.0	20
352	Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3750.	1.7	10
353	Cell-free DNA promotes malignant transformation in non-tumor cells. <i>Scientific Reports</i> , 2020, 10, 21674.	1.6	12
354	Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1430-1437.	1.2	19
355	Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?. <i>EPMA Journal</i> , 2020, 11, 603-627.	3.3	58
357	Erdheim-Chester disease: a case treated with IFN- β monitored using plasma and urine cell-free DNA. <i>Immunotherapy</i> , 2020, 12, 379-387.	1.0	2
358	Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1523-1532.	1.0	17
359	Oviz-Bio: a web-based platform for interactive cancer genomics data visualization. <i>Nucleic Acids Research</i> , 2020, 48, W415-W426.	6.5	17
360	Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 949-956.	2.1	7
361	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 95.	3.5	147
362	Graphene-Based Strategies in Liquid Biopsy and in Viral Diseases Diagnosis. <i>Nanomaterials</i> , 2020, 10, 1014.	1.9	43
363	The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1463-1475.	1.0	11

#	ARTICLE	IF	CITATIONS
364	Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification. <i>Biosensors and Bioelectronics</i> , 2020, 165, 112392.	5.3	32
365	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1566.	1.7	15
366	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	5.7	309
367	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	40
368	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	1.8	9
369	SLAM-MS: Mutation scanning of stem-loop amplicons with TaqMan probes by quantitative DNA melting analysis. <i>Scientific Reports</i> , 2020, 10, 5476.	1.6	3
370	Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 812.	1.7	30
371	Increasing the Sensitivity of Electrochemical DNA Detection by a Micropillar-Structured Biosensing Surface. <i>Langmuir</i> , 2020, 36, 4272-4279.	1.6	16
372	DNA-Templated Timer Probes for Multiplexed Sensing. <i>Nano Letters</i> , 2020, 20, 2688-2694.	4.5	13
373	PNA Clamping in Nucleic Acid Amplification Protocols to Detect Single Nucleotide Mutations Related to Cancer. <i>Molecules</i> , 2020, 25, 786.	1.7	19
374	Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor. <i>Scientific Reports</i> , 2020, 10, 2813.	1.6	38
375	Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0227294.	1.1	8
376	Enabling Precision Oncology Through Precision Diagnostics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 97-121.	9.6	50
377	PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1-Mediated Hippo/YAP/TAZ Pathway. <i>Advanced Science</i> , 2020, 7, 1900860.	5.6	27
378	Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 517-528.	1.5	60
379	A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3248-3258.	3.2	64
380	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 284-294.	1.1	12
381	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , 2021, 124, 797-804.	2.9	16

#	ARTICLE	IF	CITATIONS
382	dPCR application in liquid biopsies: divide and conquer. Expert Review of Molecular Diagnostics, 2021, 21, 3-15.	1.5	15
383	Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel ImmunoSpheres. Analytical Chemistry, 2021, 93, 1100-1109.	3.2	7
384	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Review of Gastroenterology and Hepatology, 2021, 15, 65-79.	1.4	4
385	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. British Journal of Cancer, 2021, 124, 345-358.	2.9	238
386	Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. Scientific Reports, 2021, 11, 441.	1.6	13
387	Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110015.	1.4	6
388	Circulating free <scp>DNA</scp> in the plasma of individuals with neurofibromatosis type 1. American Journal of Medical Genetics, Part A, 2021, 185, 1098-1104.	0.7	4
389	Circulating Biomarkers in Head and Neck Cancer. , 2021, , 123-142.		0
390	Cell-Free DNA: Hope and Potential Application in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 639233.	1.8	60
391	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2505-2514.	3.2	14
392	Molecular Oncology in Management of Colorectal Cancer. Indian Journal of Surgical Oncology, 2021, 12, 169-180.	0.3	0
393	Novel Biomarkers in the Diagnosis of Benign and Malignant Gastrointestinal Diseases. Digestive Diseases, 2022, 40, 1-13.	0.8	9
394	Perspectives for the analysis of circulating tumor DNA in clinical oncology: achievements and unresolved issues. Voprosy Onkologii, 2021, 67, 29-34.	0.1	0
395	Selective extraction of low-abundance BRAF V600E mutation from plasma, urine, and sputum using ion-tagged oligonucleotides and magnetic ionic liquids. Analytical and Bioanalytical Chemistry, 2022, 414, 277-286.	1.9	4
396	Update on Pulmonary Langerhans Cell Histiocytosis. Frontiers in Medicine, 2020, 7, 582581.	1.2	17
398	Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 583714.	1.3	9
399	Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. JCI Insight, 2021, 6, .	2.3	47
400	Liver metastases. Nature Reviews Disease Primers, 2021, 7, 27.	18.1	190

#	ARTICLE	IF	CITATIONS
401	The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer. <i>Current Pharmaceutical Design</i> , 2021, 27, 942-952.	0.9	2
402	Current status of ctDNA in precision oncology for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 140.	3.5	15
403	The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. <i>Blood Advances</i> , 2021, 5, 1991-2002.	2.5	15
404	Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays. <i>Cancers</i> , 2021, 13, 2718.	1.7	9
405	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with <i>RAS</i> -mutated or <i>BRAF</i> -mutated metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1385-1397.	2.3	10
406	Preclinical models and technologies to advance nanovaccine development. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 148-182.	6.6	18
407	Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?. <i>Diagnostics</i> , 2021, 11, 946.	1.3	0
408	An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. <i>Nature Biomedical Engineering</i> , 2021, 5, 678-689.	11.6	90
409	Isolation of Circulating Biomarkers for Liquid Biopsy using Immunoaffinity-Based Stimuli-Responsive Hybrid Hydrogel Beads. <i>Analysis & Sensing</i> , 2021, 1, 117-129.	1.1	3
410	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021, 15, 2401-2411.	2.1	11
411	Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression. <i>Translational Cancer Research</i> , 2021, 10, 2812-2821.	0.4	2
412	Analytical Technologies for Liquid Biopsy of Subcellular Materials. <i>Annual Review of Analytical Chemistry</i> , 2021, 14, 207-229.	2.8	2
413	Association of emergence of new mutations in circulating tumour DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 845.	1.1	0
414	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	9.4	151
415	Translational Utility of Liquid Biopsies in Thyroid Cancer Management. <i>Cancers</i> , 2021, 13, 3443.	1.7	12
416	Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results. <i>Cancers</i> , 2021, 13, 4104.	1.7	9
417	Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 16745.	1.6	13
418	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. <i>Scientific Reports</i> , 2021, 11, 16333.	1.6	14

#	ARTICLE	IF	CITATIONS
419	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. <i>Chest</i> , 2021, 160, 1095-1107.	0.4	23
420	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	1.7	8
421	Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124483.	2.8	21
422	Size distribution of cell-free DNA in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103455.	2.0	11
423	Target-mediated assembly formation of multi-arm DNAzyme nanostructures for sensitive and accurate discrimination of single-nucleotide polymorphism in K-ras gene. <i>Sensors and Actuators B: Chemical</i> , 2021, 346, 130535.	4.0	4
424	Coenzyme ^α -catalyzed electroinitiated reversible addition fragmentation chain transfer polymerization for ultrasensitive electrochemical DNA detection. <i>Talanta</i> , 2022, 236, 122840.	2.9	7
425	Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 193.	1.0	22
426	Association of the Neutrophil Extracellular Traps Formation With the Production of Circulating Cell-Free DNA and Anti-Cardiolipin Autoantibody in Patients With a Metastatic Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
427	A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.	1.5	155
428	A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care. <i>Methods in Molecular Biology</i> , 2016, 1392, 1-16.	0.4	12
429	Enrichment and Analysis of ctDNA. <i>Recent Results in Cancer Research</i> , 2020, 215, 181-211.	1.8	13
430	Review ctDNA and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 231-252.	1.8	16
431	Cell-Free DNA in the Management of Colorectal Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 253-261.	1.8	5
432	Genetic Analysis of Circulating Tumour Cells. <i>Recent Results in Cancer Research</i> , 2020, 215, 57-76.	1.8	12
433	Cancer Methylation Biomarkers in Circulating Cell-Free DNA. , 2019, , 217-245.		3
434	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102028.	3.4	9
436	Comparison of Genetic and Epigenetic Alterations of Primary Tumors and Matched Plasma Samples in Patients with Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0126417.	1.1	41
437	Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0161012.	1.1	39

#	ARTICLE	IF	CITATIONS
438	Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS ONE, 2016, 11, e0166354.	1.1	150
439	Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS ONE, 2017, 12, e0171991.	1.1	53
440	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE, 2017, 12, e0174308.	1.1	40
441	Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS ONE, 2017, 12, e0176340.	1.1	18
442	Discrimination of healthy and colorectal cancer patients using FTIR and PLS-DA. Revista Jovens Pesquisadores, 2019, 9, 115-130.	0.1	1
443	<i>KRAS</i> mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget, 2016, 7, 78827-78840.	0.8	70
444	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	0.8	60
445	Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. Oncotarget, 2017, 8, 3009-3017.	0.8	38
446	TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget, 2014, 5, 12428-12439.	0.8	58
447	Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. Oncotarget, 2019, 10, 5690-5702.	0.8	15
448	Circulating tumor DNA analysis in the era of precision oncology. Oncotarget, 2020, 11, 188-211.	0.8	54
449	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget, 2015, 6, 40026-40035.	0.8	15
450	Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy. Oncotarget, 2016, 7, 21591-21600.	0.8	21
451	Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget, 2016, 7, 64766-64777.	0.8	22
452	Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology. Current Pharmaceutical Biotechnology, 2022, 23, 112-122.	0.9	14
453	Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. Cancer Biology and Medicine, 2016, 13, 12-8.	1.4	19
454	Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy. Beilstein Journal of Nanotechnology, 2020, 11, 263-284.	1.5	9
455	Cancer biomarker discovery and validation. Translational Cancer Research, 2015, 4, 256-269.	0.4	354

#	ARTICLE	IF	CITATIONS
456	Role of circulating free DNA in colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 810.	0.8	6
457	Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biology and Medicine, 2015, 12, 87-95.	1.4	35
458	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers, 2021, 13, 5128.	1.7	6
459	ADN tumoral circulat. , 2014, , 149-157.		0
460	Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification. British Journal of Pharmacy, 2016, 1, .	0.1	0
461	Rapid and Sensitive Genotyping of Multiple Clinical Samples Based on a Combined Direct PCR and Magnetic Lateral Flow Assay. SSRN Electronic Journal, 0, , .	0.4	0
462	Biomarker for the Treatment of Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 425-434.	0.1	0
465	Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. Oncology & Hematology Review, 2019, 15, 33.	0.2	1
466	ADN tumoral circulat dans le cancer colorectal. Colon and Rectum, 2019, 13, 98-101.	0.0	0
467	Biopsia liquida: una review. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.2	0
469	A Pterin-FAM-TAMRA Tri-color Fluorescence Biosensor to Detect the Level of KRAS Point Mutation. Analytical Sciences, 2020, 36, 1529-1533.	0.8	2
470	Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247.		0
471	Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1547-1555.	1.4	5
472	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 2021, 20, 143.	7.9	117
473	Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. Current Oncology Reports, 2021, 23, 140.	1.8	3
474	Pathologic Features of Colorectal Carcinomas. , 2021, , 455-480.		2
476	Notes for developing a molecular test for the full characterization of circulating tumor cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 471-8.	0.7	1
477	Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2014, 7, S8-S12.	0.8	0

#	ARTICLE	IF	CITATIONS
478	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecanermedscience</i> , 2020, 14, 1119.	0.6	2
479	Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 15330338211039131.	0.8	0
480	Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110391.	0.8	1
481	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0
482	Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR. <i>Journal of Clinical Laboratory Analysis</i> , 2021, , e24103.	0.9	4
483	Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2021, 13, 5731.	1.7	13
484	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecanermedscience</i> , 2020, 14, 1119.	0.6	5
485	Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers. <i>Cancers</i> , 2022, 14, 288.	1.7	11
486	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. <i>IScience</i> , 2022, 25, 103826.	1.9	13
487	Nuclease-Assisted, Multiplexed Minor-Allele Enrichment: Application in Liquid Biopsy of Cancer. <i>Methods in Molecular Biology</i> , 2022, 2394, 433-451.	0.4	3
488	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
489	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100514.	0.7	5
490	Ratiometric Electrochemical Switch for Circulating Tumor DNA through Recycling Activation of Blocked DNAzymes. <i>Analytical Chemistry</i> , 2022, 94, 2779-2784.	3.2	27
491	Surface enhanced Raman spectroscopy for tumor nucleic acid: Towards cancer diagnosis and precision medicine. <i>Biosensors and Bioelectronics</i> , 2022, 204, 114075.	5.3	20
492	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. <i>Molecular Oncology</i> , 2022, 16, 2057-2070.	2.1	4
493	Reliability of BRAF mutation detection using plasma sample. <i>Medicine (United States)</i> , 2021, 100, e28382.	0.4	4
494	The Practicality of the Use of Liquid Biopsy in Early Diagnosis and Treatment Monitoring of Oral Cancer in Resource-Limited Settings. <i>Cancers</i> , 2022, 14, 1139.	1.7	19
495	Potencjalne Możliwości Wykrywania DNA HPV w Płynnej Biopsji i Diagnostyce Raka Głowy i Szyi. <i>Postępy Mikrobiologii</i> , 2022, 61, 31-38.	0.1	0

#	ARTICLE	IF	CITATIONS
496	Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Biosensors</i> , 2022, 12, 206.	2.3	6
497	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 394-407.	2.9	41
498	KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR. <i>International Journal of Colorectal Disease</i> , 2022, 37, 895-905.	1.0	3
499	Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care. <i>Diagnostics</i> , 2022, 12, 748.	1.3	9
500	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	2.0	10
501	The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer. <i>Molecular and Cellular Probes</i> , 2022, 63, 101807.	0.9	3
502	Mutation enrichment in human DNA samples via UV-mediated cross-linking. <i>Nucleic Acids Research</i> , 2022, 50, e32-e32.	6.5	7
503	Concordance between the tumor mutational status and circulating tumor DNA in patients with colorectal cancer. <i>Pelvic Surgery and Oncology</i> , 2022, 12, 27-34.	0.2	1
504	Current and Developing Liquid Biopsy Techniques for Breast Cancer. <i>Cancers</i> , 2022, 14, 2052.	1.7	19
514	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210968.	1.4	8
515	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725.	2.0	1
516	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 24113-24121.	4.0	5
517	Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. <i>British Journal of Cancer</i> , 2022, 127, 898-907.	2.9	13
521	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
522	The Promise of Circulating Tumor DNA in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 2968.	1.7	11
523	Saliva Diagnostics. <i>Annual Review of Analytical Chemistry</i> , 2022, 15, 107-121.	2.8	29
524	Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
525	The Influence of Proteins on Fate and Biological Role of Circulating DNA. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7224.	1.8	4

#	ARTICLE	IF	CITATIONS
526	Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications. <i>Cancers</i> , 2022, 14, 3143.	1.7	4
527	Liquid profiling for cancer patient stratification in precision medicine—current status and challenges for successful implementation in standard care. <i>Laboratoriums Medizin</i> , 2022, 46, 225-236.	0.1	1
528	Detection of KRAS mutations by colon and lung cancer exosomes and analysis of mutational statuses compared to primary tissue. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , .	0.2	0
529	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	27
530	Soo-PCR: Single Nucleotide Variant On-Off Discrimination — Polymerase Chain Reaction. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
531	Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery. <i>Cellular Signalling</i> , 2022, 99, 110413.	1.7	7
532	Bioplatfoms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
533	Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4101.	1.7	5
534	Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine. <i>Cancers</i> , 2022, 14, 4359.	1.7	8
535	The Role of Biomarkers in the Management of Colorectal Liver Metastases. <i>Cancers</i> , 2022, 14, 4602.	1.7	5
536	Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers — current evidence and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
537	Ultrahigh sensitive and selective detection of single nucleotide polymorphism using peptide nucleic acid and ribonuclease H assembled DNA amplification (PRADA). <i>Analytica Chimica Acta</i> , 2022, 1233, 340423.	2.6	1
538	Gold island-enhanced multiplex quantum dots fluorescent system for biomedical analysis of circulating tumor nucleic acids. <i>Nano Select</i> , 0, , .	1.9	0
539	Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management. <i>Cancers</i> , 2022, 14, 5370.	1.7	1
540	Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2022, 790, 108445.	2.4	4
541	Simple, Low-Cost, and Timely Optical Biosensors for the Detection of Epigenetic Biomarkers: The Future of Cancer Diagnosis. <i>European Medical Journal Oncology</i> , 0, , 54-61.	0.0	1
542	How ctDNA Changing the Landscape of Management of Colorectal Cancers. , 0, 1, 33-40.		0
543	High-purity isolation platelets by gradient centrifugation plus filtration. <i>International Journal of Laboratory Hematology</i> , 2023, 45, 187-194.	0.7	1

#	ARTICLE	IF	CITATIONS
544	Clinical application and detection techniques of liquid biopsy in gastric cancer. <i>Molecular Cancer</i> , 2023, 22, .	7.9	33
545	Reversible capture and release of circulating tumor cells on a three-dimensional conductive interface to improve cell purity for gene mutation analysis. <i>View</i> , 2023, 4, .	2.7	3
546	Nuclease Enrichment and qPCR Detection of Rare Nucleotide Variants. <i>Methods in Molecular Biology</i> , 2023, , 41-56.	0.4	0
547	Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. <i>Pathology Research and Practice</i> , 2023, 245, 154455.	1.0	1
548	The Role of Liquid Biopsies in Cancer Diagnosis and Prognostics. , 2022, , 1-27.		0
549	A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
550	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 102-138.	0.5	14
551	Circulating Tumor Cells and Cell-free Nucleic Acids as Biomarkers in Colorectal Cancer. <i>Current Pharmaceutical Design</i> , 2023, 29, 748-765.	0.9	4
552	Improving the Accuracy of Single-Nucleotide Variant Diagnosis Using On-Off Discriminating Primers. <i>Biosensors</i> , 2023, 13, 380.	2.3	0
553	Mutation detection of urinary cell-free DNA via catch-and-release isolation on nanowires for liquid biopsy. <i>Biosensors and Bioelectronics</i> , 2023, 234, 115318.	5.3	0
563	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
566	Liquid biopsy: creating opportunities in brain space. <i>British Journal of Cancer</i> , 2023, 129, 1727-1746.	2.9	1
567	Minor Allele Enrichment in Liquid Biopsies Using Nuclease-Assisted Elimination of Wild-Type DNA. <i>Current Cancer Research</i> , 2023, , 27-42.	0.2	0
569	Liquid Biopsy for Non-Invasive Monitoring of Tumour Evolution and Response to Therapy. , 2023, , .		3